AG
ALXN

AIA Group’s Alexion Pharmaceuticals ALXN Stock Holding History

AIA Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,423
Closed -$255K – 286
2021
Q2 		$255K Buy
+1,423
New +$244K 0.02% 193

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

AIA Group's ALXN Position: Q3 2021 in Review

AIA Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,423 shares — an estimated $255K sold.

AIA Group first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $255K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • AIA Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • AIA Group sold 1,423 Alexion Pharmaceuticals shares in Q3 2021, an estimated $255K.
  • AIA Group first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • AIA Group's Alexion Pharmaceuticals position peaked at $255K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on AIA Group's 13F filing for Q3 2021, filed 5 Nov 2021.